Effects of incorporating group visits on the metabolic control of type 2 diabetic patients;Diabetes y consulta médica grupal en atención primaria. ¿Vale la pena el cambio?

Revista Medica de Chile

Volumn 137, Issue 10, 2009, Pages 1323-1332

  Salinas Martínez, Ana María ^a   Garza Sagástegui, María Guadalupe ^a   Cobos Cruz, Reynaldo ^a   Núñez Rocha, Georgina Mayela ^a   Garza Elizondo, María Eugenia ^a   Peralta Chávez, Diana Fabiola ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Delivery of health care; Diabetes mellitus type 2; Primary health care

Indexed keywords

ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BODY MASS; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GROUP PROCESS; HEALTH CARE QUALITY; HUMAN; LONGITUDINAL STUDY; MALE; METHODOLOGY; MEXICO; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIMARY HEALTH CARE; STANDARD;

ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GROUP PROCESSES; HUMANS; LONGITUDINAL STUDIES; MALE; MEXICO; MIDDLE AGED; PRIMARY HEALTH CARE; PROGRAM EVALUATION;

EID: 71149089404     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. PAN AMERICAN HEALTH ORGANIZATION, WORLD HEALTH ORGANIZATION. Division of disease prevention and control of non-communicable diseases program. Diabetes initiative for the Americas (DIA): Action Plan for Latin America and the Caribbean 2001-2006. PAHO/HCP/ HCN/01.05. Julio 2001 http://www.paho.org/English/ AD/DPC/NC/dia-action-plan-2001-2006.PDF. Consultado el 21 de agosto, 2007.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
3. STRATTON IM, ADLER AI, ANDREW H, NEIL W, MATTHEWS DR, MANLEY SE ET AL. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
4. COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN, HITMAN GA, NEIL HA, LIVINGSTONE SJ ET AL. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial. Lancet 2004; 364: 685-96.
5. COLLINS R, ARMITAGE J, PARISH S, SLEIGH P, PETO R; HEART PROTECTION STUDY COLLABORATIVE GROUP. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005-16.
6. GOLDBERG RB, MELLIES MJ, SACKS FM, MOYÉ LA, HOWARD BV, HOWARD WJ ET AL. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-9.
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.
8. GAEDE P, VEDEL P, LARSEN N, JENSEN GV, PARVING HH, PEDERSEN O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. Engl J Med 2003; 348: 383-93.
9. SAYDAH SH, FRADKIN J, COWIE CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
10. NARAYAN KM, GREGG EW, ENGELGAU MM, MOORE B, THOMPSON TJ, WILLIAMSON DF ET AL. Translation research for chronic disease: the case of diabetes. Diabetes Care 2000; 23: 1794-8.
11. OLAIZ G, ROJAS R, BARQUERA S, SHAMAH T, AGUILAR C, CRAVIOTO Px /xet-alET AL./et-al Encuesta Nacional de Salud. 2000. La salud de los adultos. Cuernavaca: Instituto Nacional de Salud Pública, 2003; vol. 2: 95, 107.
12. GAGLIARDINO JJ, DE LA HERA M, SIRI F; GRUPO DE INVESTIGACIÓN DE LA RED QUALIDIAB. Evaluación de la calidad de la asistencia al paciente diabético en América Latina. Rev Panam Salud Publica 2001; 10: 309-17.
13. NOFFSINGER EB, SCOTT JC. Understanding today's group visit models. The Permanente Journal 2000; 4: 99-112.
14. JABER R, BRAKSMAJER A, TRILLING J. Group visits for chronic illness care: models, benefits and challenges. Fam Pract Manag 2006; 13: 37-40.
15. CLANCY DE, COPE DW, MAGRUDER KM, HUANG P, WOLFMAN TE. Evaluating concordance to American Diabetes Association standards of care for type 2 diabetes through group visits in an uninsured or inadequately insured patient population. Diabetes Care 2003; 26: 2032-6.
16. SADUR CN, MOLINE N, COSTA M, MICHALIK D, MENDLOWITZ D, ROLLER S ET AL. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care 1999; 22: 2011-7.
17. TRENTO M, PASSERA P, TOMALINO M, BAJARDI M, POMERO F, ALLIONE A ET AL. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care 2001; 24: 995-1000.
18. TRENTO M, PASSERA P, BORGO E, TOMALINO M, BAJARDI M, CAVALLO F ET AL. A 5-Year Randomized Controlled Study of Learning, Problem Solving Ability, and Quality of Life Modifications in People With Type 2 Diabetes Managed by Group Care. Diabetes Care 2004; 27: 670-5.
19. Información Estadística en Salud del Instituto Mexicano del Seguro Social. www.imss.gob.mx. Consultado el 18 de septiembre, 2007.
20. a Edición. Oxford: Blackwell Science, 1987.
21. AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30: S4-S41.
22. GRAHAM I, ATAR D, BORCH-JOHNSEN K, BOYSEN G, BURELL G, CIFKOVA R ET AL. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2007; 28: 2375-414.
23. ORGANIZACIÓN MUNDIAL DE LA SALUD. Obesidad y sobrepeso. http://www.who.int/mediacentre/factsheets/ fs311/es/index.html. Consultado el 21 de agosto, 2007.
24. Secretaría de Salud. Norma Oficial Mexicana NOM-015-SSA2-1994, para la prevención, tratamiento y control de la diabetes. http://www.salud.gob.mx/ unidades/cdi/nom/m015ssa24.html. Consultado el 21 de agosto, 2007.
25. HOJAT M, XU G. A visitor's guide to effect sizes: statistical significance versus practical (clinical) importance of research findings. Adv Health Sci Educ Theory Pract 2004; 9: 241-9.
26. TIEN KJ, HUNG HC, HSIAO JY, HSU SC, HSIN SC, SHIN SJ, HSIEH MC. Effectiveness of comprehensive diabetes care program in Taiwanese with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 276-83.
27. WILLIAMS KV, BERTOLDO A, KINAHAN P, COBELLI C, KELLEY DE. Weight loss-induced plasticity of glucose transport and phosphorylation in the insulin resistance of obesity and type 2 diabetes. Diabetes 2003; 52: 1619-26.
28. REDMON JB, RECK KP, RAATZ SK, SWANSON JE, KWONG CA, JI H ET AL. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care 2005; 28: 1311-5.
29. WOERLE HJ, NEUMANN C, ZSCHAU S, TENNER S, IRSIGLER A, SCHIRRA J ET AL. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280-5.
30. EL-KEBBI IM, ZIEMER DC, GALLINA DL, PHILLIPS LS. Diabetes in urban African-Americans. VI. Utility of fasting or random glucose in identifying poor glycemic control. Diabetes Care 1998; 21: 501-5.
31. AL-LAWATI JA, AL-LAWATI AM. The utility of fasting plasma glucose in predicting glycosylated hemoglobin in type 2 diabetes. Ann Saudi Med 2007; 27: 347-51.
32. LERMAN-GARBER I, LÓPEZ-PONCE A, MURCIO-FLORES RA, BRITO-CÓRDOVA GX, VELASCO-PÉREZ ML, VILLA AR ET AL. Comparing easy and accessible parameters of glycemic control in type 2 diabetes. Rev Invest Clin 2001; 53: 518-25.
33. VAN DER VEN NC. Psychosocial Group Interventions in Diabetes Care. Diabetes Spectrum 2003; 16: 88-95.